Highest-materiality recent filing
Richard Kollender re-elected as Class II Director with 23,180,585 votes for, 1,998,525 withheld, 11,920,445 broker non-votes.
RPID raises ~$9M in underwritten common stock and warrant offering; insiders add $140K
Underwritten offering of 3.58M units (share + two warrants) at $1.955/unit; net proceeds ~$8.9M.
Rapid Micro Biosystems Q1 revenue up 11% to $8.0M; net loss widens to $14.3M
Total revenue $8.0M (+11% YoY); product revenue $5.6M (+36%).
COO John Wilson departs April 10; CEO Spignesi assumes operating role
John Wilson, COO, will leave as of April 10, 2026 for family reasons; no disagreement with the Company.
Q4 total revenue $11.3M (+37% YoY); product revenue $9.3M (+78%).
Rapid Micro Biosystems pre-announces record Q4 rev $11.3M (+37% YoY); FY rev $33.6M (+20%)
Q4 2025 total revenue expected ~$11.3M, up ~37% YoY; record multi-system order from Top 20 biopharma customer.
Q3 2025 revenue $7.8M (+3% YoY); recurring revenue up 32% to $4.8M on record consumables.
Rapid Micro Biosystems Q2 revenue $7.3M (+10% YoY); enters $45M term loan with Trinity Capital
Q2 2025 revenue $7.3M, up 10% YoY; net loss $11.9M ($0.27/sh) vs $12.6M ($0.29) prior year.
CEO Robert Spignesi diagnosed with treatable lymphoma; will continue to lead company
CEO Robert Spignesi disclosed a recent diagnosis of a treatable form of lymphoma.
Director Jeffrey Schwartz resigns from Rapid Micro Biosystems board effective May 22, 2025
Jeffrey Schwartz resigned as director and chair of nominating and corporate governance committee; not due to any disagreement.
Rapid Micro Q1 revenue $7.2M (+28% YoY), gross margin turns positive 6%, net loss narrows to $11.3M
Product revenue $4.1M (+10%), service revenue $3.1M (+64%) driven by record validation activity; 3 new Growth Direct placements.
Rapid Micro Biosystems updates corporate presentation for investor meetings
Company furnished a corporate presentation dated March 4, 2025, via 8-K under Item 7.01.
Q4 2024 revenue $8.2M (up 30% vs $6.3M in Q4 2023); product revenue $5.2M (+27%), service revenue $3.0M (+35%).
Rapid Micro Biosystems signs global distribution deal with Merck KGaA's MilliporeSigma
MilliporeSigma gets co-exclusive global rights to sell Growth Direct systems and consumables in pharma, med device, personal care, cosmetics, food & beverage.
Rapid Micro Biosystems posts updated corporate presentation; no material financial updates
Filed an updated corporate presentation on January 16, 2025 for use with investors.
Rapid Micro prelim Q4 rev record $8.2M, +30% YoY; Lonza collaboration
Q4 total revenue preliminary ~$8.2M (record), +30% YoY; recurring rev ~$4.2M, +27% YoY.
Rapid Micro Biosystems regains Nasdaq minimum bid price compliance
Received Nasdaq letter on Nov 11, 2024 confirming compliance with $1.00 minimum bid price rule.
RPID Q3 rev $7.6M (+24%), gross margin turns positive; director resigns
Revenue $7.6M (+24% YoY); seven Growth Direct placements; gross margin positive 8% vs -27% last year.
Rapid Micro Biosystems Q2 revenue up 32% to $6.6M; Nasdaq transfer due to bid price deficiency
Q2 revenue $6.6M (+32% YoY); net loss $12.6M ($0.29 loss per share) vs $14.0M loss a year ago.
RPID shareholders approve officer exculpation charter amendment, elect three directors
Stockholders approved Certificate of Amendment to allow officer exculpation under Delaware law; effective May 23, 2024.
Rapid Micro Biosystems Q1 revenue $5.6M (+11% YoY), loss $13.3M; reaffirms FY guidance
Q1 revenue $5.6M (+11% YoY); net loss $13.3M ($0.31/share).
Rapid Micro Biosystems Q4 revenue $6.3M (+45% YoY); guides FY2024 revenue ≥$27M
Q4 2023 revenue $6.3M (+45% YoY); placed 6 Growth Direct systems, highest since Q3 2021.
Rapid Micro Biosystems receives Nasdaq delisting notice for bid price below $1.00
Nasdaq notified RPID on Feb 2, 2024, that bid price closed below $1.00 for 30 consecutive business days (Dec 18, 2023 - Feb 1, 2024).
Rapid Micro Q4 rev ~$6.2-6.4M (+45%); FY rev ~$22.4-22.6M (+30%); cash $95M runway into H2 2026
Q4 revenue expected $6.2-6.4M (+45% YoY); FY23 revenue $22.4-22.6M (+30% YoY).
Rapid Micro Biosystems Q3 revenue $6.1M (+30% YoY); reaffirms FY23 guidance at least $22M
Q3 revenue $6.1M, up 30% YoY; placed 5 Growth Direct systems, validated 4.
Rapid Micro Biosystems regains Nasdaq minimum bid price compliance
Received Nasdaq deficiency notice on Sept 13 after bid price below $1 for 30 consecutive days (July 31-Sept 11).
Rapid Micro Biosystems receives Nasdaq delisting notice over bid price below $1.00
Received Nasdaq deficiency notice on Sept 13, 2023; bid price below $1.00 for 30 consecutive business days ending Sept 11, 2023.
Q2 revenue $5.0M (+30% YoY); net loss $14.0M; reaffirms FY2023 guidance
Total revenue $5.0M, up 30% from $3.9M in Q2 2022; net loss $14.0M ($0.33 per share) vs $13.1M ($0.31).
Rapid Micro Biosystems appoints Kirk Malloy as Chair of Board, expands board to eight
Kirk Malloy appointed as Class III director and Chair of Board, effective July 14, 2023.
Rapid Micro Biosystems stockholders elect Schwartz, Kollender, Ricciardi as Class II directors
Jeffrey Schwartz received 26,007,817 votes for and 1,756,781 withheld; broker non-votes 7,071,880.
Rapid Micro Biosystems Q1 revenue $5.0M (+21% YoY); reaffirms FY23 guidance of at least $22.0M
Total revenue $5.0M, up 21% YoY; recurring revenue $3.3M (+22%).
Rapid Micro Biosystems Q4 commercial revenue $4.4M, FY2022 $17.1M; guides FY2023 at least $22M
Q4 2022 commercial revenue $4.4M (vs $4.9M prior year); net loss $16.4M ($0.39 per share).
Rapid Micro Biosystems prelim FY2022 revenue $17.0-17.2M; Q4 $4.2-4.4M; cash $140M
FY2022 commercial revenue expected $17.0-17.2M; Q4 revenue $4.2-4.4M, in line with expectations.
Rapid Micro Biosystems ends strategic review; no binding offers received for sale
Board concludes review of strategic alternatives that began August 2022; no parties submitted binding offers to acquire all outstanding shares.
Rapid Micro Biosystems Q3 commercial revenue $4.7M, net loss $16.3M, reaffirms FY2022 guidance
Commercial revenue $4.7M (down 25% YoY from $6.3M); recurring revenue up 34% to $2.9M.
Rapid Micro Biosystems Q2 revenue $3.9M; lowers FY22 outlook to ≥$17M, cuts 20% workforce
Q2 commercial revenue $3.9M vs $5.7M YoY; net loss $13.1M ($0.31 loss per share).
Rapid Micro Biosystems elects two Class I directors, ratifies auditor
David Hirsch (26.8M for, 4.1M withheld) and Inese Lowenstein (31.0M for, 16k withheld) elected to board until 2025.
Commercial revenue $4.2M (Q1 2021: $4.8M, including $0.2M BARDA); recurring revenue up 66% to $2.7M.
Director Alexander Schmitz to not stand for reelection at 2022 annual meeting
Alexander Schmitz, independent Class I director, will not seek reelection at the 2022 Annual Meeting.
Rapid Micro Biosystems FY2021 commercial revenue up 54% to $21.6M; net loss $73.5M
FY2021 total revenue $23.2M vs $16.1M; commercial revenue $21.6M (+54%); net loss $73.5M vs $37.1M.
Rapid Micro Bio pre-announces Q4 rev $4.7-5.2M; FY22 outlook $27-32M
Preliminary Q4 total revenue $4.7M-$5.2M; commercial $4.5M-$4.9M; non-commercial (BARDA) $0.2M-$0.3M.
Rapid Micro Biosystems appoints Inese Lowenstein to Board of Directors; 25,000 options granted
Lowenstein appointed as Class III director effective Dec 17, 2021; term expires at 2024 annual meeting.
Rapid Micro Biosystems Q3 commercial revenue $6.3M (+27%); reaffirms FY21 outlook
Commercial revenue $6.3M (+27% YoY); recurring commercial revenue $2.2M (+154% YoY).
Rapid Micro Biosystems pays $28.7M to terminate Kennedy Lewis loan, releases liens
Paid $28.7M to terminate Loan and Security Agreement with Kennedy Lewis Management LP.
Rapid Micro Q2 commercial revenue $5.7M (+135% YoY); full-year outlook at least $24M
Q2 total revenue $6.1M vs $2.6M YoY; net loss ($11.8M) vs ($9.3M) YoY.
Rapid Micro Biosystems files restated certificate and bylaws effective with IPO closing
Filed restated certificate with Delaware on July 19, 2021, effective upon IPO closing.
On May 22, 2025, Jeffrey Schwartz notified Rapid Micro Biosystems, Inc. (the "Company") of his resignation from the board of directors of the Company and all committees thereof, effective as of May 22, 2025.
On October 29, 2024, David Hirsch, M.D., Ph.D., notified the Company of his resignation from the board of directors of the Company and all committees thereof, effective as of November 1, 2024.
Jeffrey Schwartz resigned as Chair of the Board as of the Effective Date and will continue to serve as a member of the Board.
appointed Kirk D. Malloy, Ph.D. to serve as a Class III member of the Board and Chair of the Board, effective as of July 14, 2023 (the “Effective Date”).
Mr. Keys’ last date of employment with the Company as its Chief Commercial Officer was August 11, 2022
On March 23, 2022, Alexander Schmitz, a member of the Board of Directors (the “Board”) of Rapid Micro Biosystems, Inc. (the “Company”) informed the Company that he does not intend to stand for reelection at the Company’s 2022 annual meeting of stockholders (the “Annual Meeting”).
On December 17, 2021, the Board of Directors (the “Board”) of Rapid Micro Biosystems, Inc. (the “Company”) appointed Inese Lowenstein to the Board.
Max materiality 0.85 · Median 0.65 · Most common event earnings